TITLE:
An Open-Label Safety Program for the Use of Zalcitabine (Dideoxycytidine; ddC) in Pediatric Patients With Symptomatic HIV Infection Who Have Failed or Are Intolerant to AZT Monotherapy, or Who Have Completed Other ddC Protocols, or Are Ineligible for Other Ongoing Clinical Studies

CONDITION:
HIV Infections

INTERVENTION:
Zalcitabine

SUMMARY:

      To allow, on a compassionate use basis, zalcitabine (ddC) for pediatric patients with
      symptomatic HIV disease who have failed treatment or who are intolerant to zidovudine (AZT),
      or who have completed other ddC protocols, or who are ineligible for ongoing clinical
      trials.
    

DETAILED DESCRIPTION:

      Patients receive ddC and are evaluated at study entry and every 3 months thereafter, until 3
      months after ddC becomes approved for pediatric patients or the sponsor deems it necessary
      to terminate the protocol.
    

ELIGIBILITY:
Gender: All
Age: 3 Months to 11 Years
Criteria:

        Inclusion Criteria

        Patients must have:

          -  Symptomatic HIV infection.

          -  Failure on or intolerance to AZT monotherapy OR completed other ddC protocols OR been
             ineligible for other ongoing clinical trials.

          -  Consent of parent or guardian required.

        Note:

          -  Patients who do not meet the eligibility requirements may discuss their cases with
             the medical monitor.
      
